

JUL. 12. 2006 3:18PM

NO. 082 P. 1

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
TEL: 202.739.3000
FAX: 202.739.3001
eFax: 877.432.9652
www.morganlewis.com

Morgan Lewis
COUNSELORS AT LAW

DRAFT

SEND TO

Name: Michael Brannock, Ph.D. Firm: United States Patent and
Trademark Office
FAX #: 571-273-0869 Telephone #:

FROM

Name: Christopher J. Betti Floor: 3
Operator Sending: Telephone # 202.739.5745
FAX #: 877.432.9652 Date Sent: July 12, 2006 No of Pages: 17
(including cover page)

FAX MESSAGE

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE NAMED RECIPIENT(S). THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

COMMENTS

RE: U.S. Patent Application of: Gerlinde LENZEN *et al.*
Application No.: 09/319,724
For: *Mammalian ICYP Receptor and its Applications*

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
Tel: 202.739.3000
Fax: 202.739.3001
www.morganlewis.com

Morgan Lewis
C O U N S E L O R S A T L A W

Christopher J. Betti, Ph.D.
cbetti@morganlewis.com
202-739-5745
Admitted in IL Only

Betti WEIMAR.

July 12, 2006

VIA FAX

PRIVILEGED AND CONFIDENTIAL

Michael Brannock, Ph.D.
United States Patent & Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
Alexandria, VA 22314

DRAFT

Re: U.S. Application No. 09/319,724
Inventors: Gerlinde LENZEN, *et al.*
For: *Mammalian ICYP Receptor and its Applications*
Our Reference: 045636-5025-US

Dear Michael,

Further to our conversation of July 12, 2006, enclosed please find a listing of claims containing proposed claim amendments for the above-referenced application.

Additionally, we provide herein references to address the 112 (enablement) rejection, exhibits 1-3: (1) Kundra, *et al.* (1994) Nature 367: 474-476; (2) Yenush, *et al.* (1994) J. Biol. Chem. 269: 100-104; and (3) and Cunningham *et al.* Science 251: 1233-1236. Briefly, we believe that at the priority date, a skilled artisan could readily prepare recombinant cells expressing a given receptor by transforming host cells with a gene encoding a receptor protein. Therefore, for those skilled in the art, it was common practice to evaluate chemotaxis by means of recombinant cells expressing a given receptor.

We thank you for reconsidering the rejections in the above-mentioned application and look forward to discussing this matter with you on Thursday July 13, 2006.

With best regards,

Christopher J. Betti

Christopher J. Betti, Ph.D.

cc: Elizabeth Weimar
Enclosure